MedTrace Logo

Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

NCT00209677 · Status: SUSPENDED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2007-11-01

No results posted yet for this study

Summary

To assess the usefulness of Gemcitabine plus S-1 therapy based on the antitumor effect and survival period. By performing a phase I/II study of this combination in patients with inoperable or with postoperative pancreatic cancer.

Conditions

Interventions

DRUG

Gemcitabine

DRUG

S-1

Sponsors & Collaborators

  • Hokkaido University Hospital

    collaborator OTHER

  • Hokkaido Gastrointestinal Cancer Study Group

    lead OTHER

Principal Investigators

  • Masahiro Asaka, MD, PhD · Hokkaido Gastrointestinal Cancer Study Group

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Completion
2007-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00209677 on ClinicalTrials.gov